A Community Population Screening Cohort Study Based on Polygene Methylation Detection for Colorectal Cancer in Yangzhou

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

This is a cross-sectional cohort study based on community population jointly developed by Northern Jiangsu People's Hospital and Shanghai Kunyuan Biological Technology Co., LTD. This study will verify the real world results of polygene methylation detection of colorectal cancer in a large prospective cohort of community population, which is expected to enroll 80,000 permanent residents in Yangzhou city. The preliminary design period of the study is 5 years. In this study, questionnaire survey and polygene methylation test of colorectal cancer were used as the primary screening method, and colonoscopy was used as the further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination. The evaluation indexes include sensitivity, specificity, detection rate of precancerous lesions and adenoma.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 74
Healthy Volunteers: t
View:

• 1\) Permanent resident population of Yangzhou; 2) Chronological age: 40\

⁃ 74 years, including critical value (refer to birth date of id card); 3) Have full capacity of conduct; 4) After enrollment, they could voluntarily cooperate to complete the Colorectal cancer Risk Factor Assessment Questionnaire and accept telephone follow-up; 5) Agree to timely feed back the information related to tumor diagnosis to the investigator during the study process; 6) Willing and able to sign informed consent.

Locations
Other Locations
China
Northern Jiangsu People's Hospital
RECRUITING
Yangzhou
Yangzhou First People's Hospital
RECRUITING
Yangzhou
Contact Information
Primary
Liu Jun, Master
sbyy_liujun@163.com
18051061318
Backup
Liu Rui, Doctor
rliu@singleragenomics.com
Time Frame
Start Date: 2022-04-01
Estimated Completion Date: 2027-04
Participants
Target number of participants: 80000
Treatments
Positive group
subjects received colorectal cancer polygene methylation test at baseline, and all positive results were included in the positive group. They will undergo further FIT testing, blood carcinoembryonic antigen testing and colonoscopy within three months of colorectal cancer polymethylation testing.
Related Therapeutic Areas
Sponsors
Collaborators: Northern Jiangsu People's Hospital
Leads: Singlera Genomics Inc.

This content was sourced from clinicaltrials.gov